

A unique inhibitor conformation selectively targets Gram+ bacterial DNA replication

Nat Commun (2025)

Mia Urem

Experimental Bacteriology,

LUCID (Leiden University Center for Infectious Diseases), LUMC



LED3 PhD/Postdoc symposium 2026

Art by
Ella Maru Studio

The urgent need for novel antibiotics

- Predicted to cause 10 million deaths annually by 2050 (WHO)
- Last 30 years: only 1 novel antibiotic with new mode-of-action



We need:

- new chemotypes
- new targets

PolC is a clinically unexploited target

- Only in low-GC Gram+ bacteria → specific
- The replicative DNA polymerase → essential
- Distinct from human polymerase → druggable



Clostridioides difficile




Staphylococcus aureus



Enterococcus faecium

CDC:
Antibiotic
Resistance
Threats in the
United States,
2019

First-in-class PolC inhibitor: ibezapolstat




PolC-
binding

guanine
core

Acurx Pharmaceuticals

- Mimics **guanine** (DNA building block)
- Competes with d**G**TP to inhibit replication
- Phase 3 trials for *C. difficile* infections
- Narrow spectrum: microbiome-sparing

Expanding PolC inhibition beyond *C. diff*: ACX-801



PolC-
binding

guanine
core

Acurx Pharmaceuticals


- IBZ: only suitable in gastro-intestinal tract
- ACX: modified **core** improves absorption
- Infections: *S. aureus*, *E. faecium*
- PolC-specificity via **N2-aromatic** group

Disrupting DNA replication is detrimental & PolC-specific

Polymerase activity → inhibition

PolC polymerases


$IC_{50} \leq 15 \mu\text{M}$



Bacterial growth → inhibition


Gram+ species

$MIC \leq 2 \text{ mg/L}$




PolC polymerase active site is conserved

- *E. faecium* PolC: representative model of Gram+ bacteria
- Key residues & pocket: conserved in >220 other Gram+ species




1 2 3 4 5 6 7 8 9
Variable Conserved



Polymerase active site
dGTP from *Geob* PolC structure


Inhibitors base-pair with template dCMP



dCMP:dGTP


Evans (2008) *Proc Natl Acad Sci*

3F2C




dCMP:IBZ

9QRL



dCMP:ACX-801

9QPC




Geobacillus PolC
with DNA & dGTP


Evans (2008) *Proc Natl Acad Sci*

- Occupy polymerase active site
- Bind in place of dGTP
- Competition blocks DNA extension

Key: non-planar conformation in the bound state





- Prediction: lowest energy conformation → planar (grey)
- **Structure:** N2-aromatic group almost perpendicular to nucleobase



N2-aromatic inhibitory group anchored within PolC


- Binding pocket: 4 aromatic residues
- Interactions with inhibitory group
- **F1276**: also edge-to-face with interactions with nucleobase **core**




Induced fit: F1276 is the gatekeeper of the binding pocket



ACX-801 vs apo




F1276 is also a hotspot for lab-evolved mutations




- No resistance observed in *Cdiff* clinical isolates (van Eijk (2019), Murray (2020), Bassères (2024))

- F1276 is most common



Key for PolC inhibition: non-planar inhibitor conformation & induced-fit

- Cryo-EM structures were essential to determine binding mode
 - Non-planar inhibitor: anchored to PolC while base-pairing DNA
 - Induced fit: pocket absent in apo
 - F1276: gatekeeper & hotspot for mutations
- IBZ progressing to Ph. 3 clinical trials
- Structure provides a framework for future inhibitor design





Leiden University
Medical Center

POLSTOP team

Annemieke Friggen, Nina Musch,
Wiep Klaas Smits & Meindert Lamers

Michael H. Silverman, Christopher J. Swain,
Michael R. Barbachyn, Lawrence I. Mortin,
Xiang Yu & Robert J. DeLuccia





Urem et al. *Nat Commun* (2025)

Acurx Pharmaceuticals

NL Health~Holland

 **NEMI** **NeCEN**





Condition	IC ₅₀ (uM)
PolC + IBZ	9
PolC + ACX-801	5
PolC ^{F1276L} + IBZ	993
PolC ^{F1276L} + ACX-801	717
PolC ^{F1276S} + IBZ	66
PolC ^{F1276S} + ACX-801	1545

The aromatic residues are highly conserved in PolC

